5-Fluorouracil-induced coronary vasospasm

Journal of Cardiovascular Medicine

Volumn 11, Issue 4, 2010, Pages 281-284

  Bathina, Jaya D ^a   Yusuf, Syed Wamique ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

5 fluorouracil; Capecitabine; Coronary vasospasm

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLYCERYL TRINITRATE; NIFEDIPINE; OXALIPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; RECTUM CANCER;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARDIOTOXINS; CORONARY VASOSPASM; FEMALE; FLUOROURACIL; HUMANS;

EID: 77949437619     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32832e934b     Document Type: Article

References (27)

1. De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795-1801.
2. Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995; 49:282-283.
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
4. Labianca R, Beretta G, Clerici M. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68:505-510.
5. Schober C, Papageorgiou E, Harstrick A, Bokemeyer C, Mugge A, Stahl M, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72:2242-2247.
6. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1993; 71:493-509.
7. Coronel B, Madonna O, Mercatello A, Caillette A, Moskovtchenko JF. Myocardiotoxicity of 5 fluorouracil. Intensive Care Med 1988; 14:429-430.
8. Saif MW, Szabo E, Grem J, Hamilton M. The clinical syndrome of 5-fluorouracil cardiotoxicity [abstract #1613]. Proc Am Soc Clin Oncol 2001;20.
9. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30:871-879.
10. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996; 10:805-819.
11. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65:885-889.
12. Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME. 5-fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994; 10:861-864.
13. Lemaire L, Malet-Martino MC, De Forni M, Martino R, Lasserre B. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992; 66:119-127.
14. Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control 2004; 11:46-49.
15. Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J 1991; 12:468-470.
16. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4:1-5.
17. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53:3028-3033.
18. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, et al. 5-fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15:661-664.
19. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58:487-493.
20. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33:1060-1070.
21. Rezkalla S, Kloner RA, Ensley J, Al-Sarraf M, Revels S, Olivenstein A, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7:509-514.
22. Sestito A, Sgueglia GA, Pozzo C, Cassano A, Barone C, Crea F, et al. Coronary artery spasm induced by capecitabine. J Cardiovasc Med 2006; 7:136-138.
23. Coughlin S, Das S, Lee J, Cooper J. Capecitabine induced vasospastic angina. Int J Cardiol 2008; 130:e34-e36.
24. Chu E, Schulman KL, Zelt S, Song X. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer 2009; 115:1412-1423.
25. Rastogi N, Chag M, Ayyagari S. Myocardial ischemia after 5-fluorouracil chemotherapy. Int J Cardiol 1993; 42:285-287.
26. Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer 2009; 8:55-58.
27. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer Chemother Pharmacol 1999; 43:157-161.